Licogliflozin is a drug which acts as an SGLT2 inhibitor.

It was originally developed as a potential treatment for obesity,[1] but has also been investigated for other applications such as treating symptoms of polycystic ovary syndrome and nonalcoholic steatohepatitis.

[2][3]